Serotonin Reuptake Inhibitor (Paxil) Does Not Prevent the Vasovagal Reaction Associated With Carotid Sinus Massage and/or Lower Body Negative Pressure in Healthy Volunteers

Background—The purpose of this study was to assess the effect of the serotonin reuptake inhibitor paroxetine hydrochloride (Paxil, SmithKline Beecham) on cardiovascular reflexes. We hypothesized that Paxil prevents neurally mediated syncope (NMS) by attenuating the sympathoinhibition and vagotonia associated with a vasovagal reaction. Methods and Results—In a double-blind randomized study, 25 healthy subjects with a positive response to either carotid sinus massage (CSM) or lower body negative pressure (LBNP) received Paxil (20 mg/d) or placebo for 6 weeks. Arterial baroreflex sensitivity (BRS), muscle sympathetic nerve activity (SNA), baroreflex control of SNA, blood pressure, and heart rate responses to CSM and LBNP were measured at baseline and at 6 weeks. Nineteen subjects completed the study (Paxil, n=9; placebo, n=10). In the Paxil group, BRS decreased significantly compared with baseline (15.8±4.0 ms/mm Hg versus 11.0±2.6 ms/mm Hg, P =0.05); however, all 9 subjects continued to have a positive response to LBNP with presyncope. Paxil did not attenuate the sympathoinhibition or vagotonia associated with a positive LBNP response and had no significant effect on baroreflex control of SNA. In the control group, no significant change in BRS was noted compared with baseline. Seven out of 9 subjects who had a positive LBNP response at baseline had a repeat positive LBNP response, and the subject with a positive CSM at baseline had a negative response at 6 weeks. Conclusions—Paxil decreases arterial BRS but does not prevent the presyncope associated with LBNP. The effect of Paxil on the autonomic reflexes in patients with neurally mediated syncope remains unclear.

[1]  W. Kapoor,et al.  Syncope of unknown origin. The need for a more cost-effective approach to its diagnosis evaluation. , 1982, JAMA.

[2]  J S Floras,et al.  Attenuated cardiac baroreflex in men with presyncope evoked by lower body negative pressure. , 2001, Clinical science.

[3]  D L Eckberg,et al.  Vagal and sympathetic mechanisms in patients with orthostatic vasovagal syncope. , 1997, Circulation.

[4]  W. Shen,et al.  Vasovagal Syncope , 2000, Annals of Internal Medicine.

[5]  R. Page,et al.  Baroreflex gain predicts blood pressure recovery during simulated ventricular tachycardia in humans. , 1999, Circulation.

[6]  K. Oldroyd,et al.  Role of endogenous opioids and catecholamines in vasovagal syncope. , 1996, European heart journal.

[7]  D. Kosinski,et al.  Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. , 1994, Journal of the American College of Cardiology.

[8]  R Furlan,et al.  Sympathetic and baroreceptor reflex function in neurally mediated syncope evoked by tilt. , 1997, The Journal of clinical investigation.

[9]  W. Kapoor,et al.  Evaluation and Outcome of Patients with Syncope , 1990, Medicine.

[10]  B. Grubb,et al.  Usefulness of Fluoxetine Hydrochloride for Prevention of Resistant Upright Tilt Induced Syncope , 1993, Pacing and clinical electrophysiology : PACE.

[11]  W. Kapoor,et al.  Evaluation and management of the patient with syncope. , 1992, JAMA.

[12]  D. Kosinski,et al.  Treatment of Malignant Neurocardiogenic Syncope with Dual Chamber Cardiac Pacing and Fluoxetine Hydrochloride , 1995, Pacing and clinical electrophysiology : PACE.

[13]  D. Kosinski,et al.  Neurally mediated syncope with an update on indications and usefulness of head-upright tilt table testing and pharmacologic therapy. , 1994, Current opinion in cardiology.

[14]  K. Fuxe,et al.  Evidence for the existence of monoamine neurons in the central nervous system , 1965, Zeitschrift für Zellforschung und Mikroskopische Anatomie.

[15]  D. Kosinski,et al.  Use of Serotonin Re‐Uptake Inhibitors as Primary Therapy for Carotid Sinus Hypersensitivity , 1997, Pacing and clinical electrophysiology : PACE.

[16]  S. Peroutka,et al.  Serotonin receptor and reuptake sites: pharmacologic significance. , 1990, The Journal of clinical psychiatry.

[17]  A. Ramage,et al.  Influence of 5‐HT1A Receptor Agonists on Sympathetic and Parasympathetic Nerve Activity , 1990, Journal of cardiovascular pharmacology.

[18]  A. Mark,et al.  Serotonergic mechanisms mediate renal sympathoinhibition during severe hemorrhage in rats. , 1988, The American journal of physiology.

[19]  R. Page,et al.  Effect of P-Wave Timing During Supraventricular Tachycardia on the Hemodynamic and Sympathetic Neural Response , 2001, Circulation.

[20]  A. Barsotti,et al.  Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. , 1999, Journal of the American College of Cardiology.

[21]  G GOERANSSON,et al.  THE METABOLISM OF FATTY ACIDS IN THE RAT. VI. ARACHIDONIC ACID. , 1965, Acta physiologica Scandinavica.

[22]  B. Grubb,et al.  The Use of Serotonin Reuptake Inhibitors for the Treatment of Recurrent Syncope Due to Carotid Sinus Hypersensitivity Unresponsive to Dual Chamber Cardiac Pacing , 1994, Pacing and clinical electrophysiology : PACE.